Searchable abstracts of presentations at key conferences in endocrinology

ea0002oc16 | Neuroendocrinology | SFE2001

Efficacy of the new Long-Acting Lanreotide Formulation (Lanreotide Autogel) in Patients with Acromegaly

Cullen D , Grossman A , Reckless J

Lanreotide (LAN) Autogel, a new aqueous preparation of lanreotide acetate, was administered by deep sc injection every 4 weeks to patients with acromegaly (54 males, 53 females, mean age 53 plus/minus 1 year) who had previously been responsive to im SR LAN 30 mg microparticles. Patients who had been treated with at least 4 im injections of SR LAN 30 mg every 14 (49%), 10 (32%) or 7 days (20%) for at least 3 months and had a mean GH level <10 ng/ml, were switched to LAN Auto...

ea0005p208 | Reproduction | BES2003

Pharmacokinetics and tolerability of a new a bioadhesive buccal testosterone tablet in testosterone deficient men

Ross R , Jabbar A , Jones H , Roberts B , Dunkley K , Long A , Levine H , Cullen D

Pharmacokinetics and tolerability of a new a bioadhesive buccal testosterone tablet in testosterone deficient men.RJM Ross, A Jabbar, H Jones, B Roberts, K Dunkley, A Long, H Levine, DR CullenObjectives: A phase I single centre, open label study of the pharmacokinetics and tolerability of a buccal testosterone tablet (COL1621). Design: The study was approved by The South Sheffield Ethics Committee. Twelve testosterone deficient males were treated with the buccal tablet...